A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity

By Alessandro Dario   Giustino Tomei  

Drug Safety, Vol. 27, Iss. 11, 2004-01 ,pp. : 799-818

Adis International

Access to resources Recommend Favorite

Cost effectiveness of tizanidine and baclofen similar in spasticity

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 381, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Comparison of Tizanidine and Baclofen in the Management of Spasticity

By Rushton D.N.  

PharmacoEconomics, Vol. 20, Iss. 12, 2002-01 ,pp. : 827-837

Adis International

Access to resources Recommend Favorite

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency

By Staidle Jonathan P   Dabade Tushar S   Feldman Steven R  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2041-2054

Informa Healthcare

Access to resources Recommend Favorite

Intrathecal baclofen, a GABAB receptor agonist, inhibits the expression of p-CREB and NR2B in the spinal dorsal horn in rats with diabetic neuropathic pain

By Liu Peng   Guo Wen-Ya   Zhao Xiao-Nan   Bai Hui-Ping   Wang Qian   Wang Xiu-Li   Zhang Ying-Ze  

Canadian Journal of Physiology and Pharmacology, Vol. 92, Iss. 8, 2014-01 ,pp. : 655-660

NRC Research Press

Access to resources Recommend Favorite